We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

MAI Capital Management decreased its stake in Sanofi (NASDAQ:SNY – Free Report) by 38.2% during the 3rd quarter, ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

The FDA posted a summary of observations made from the Agency’s inspection of a Regeneron (REGN) facility in Ireland that was conducted from ...

The top spenders in the space, however, are Sanofi and Regeneron. The companies marketed Dupixent (dupilumab), a biologic ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter 2024 investor letter. A ...

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

This valuation is dirt cheap for a solid biotech company with a robust pipeline. Robust Pipeline To Pump Out Future Growth Regeneron's top blockbuster drug, Dupixent, was recently approved by the FDA ...

Best Genomics Stocks To Buy Right Now. Genomics is the study of genes and how they function. Many rapidly growing companies ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.